Pioneering Biologic Drug Development in Southeast Asia
Kalbe Genexine Biologics (KGbio), established in 2016, is a joint venture between Kalbe Farma, the Southeast Asia's largest public pharmaceutical company, and Genexine, a clinical stage biotechnology company.
OUR VISION: To be the leader in biologic drug development in Southeast Asia.
OUR MISSION: To provide innovative biologic and immuno-oncology products, and better solutions in treating human diseases.
OUR BUSINESS: We are an innovative drug development company, focusing on
pre-clinical and clinical development, CMC process development, regulatory and quality compliance.
Leveraging Kalbe's manufacturing and commercial infrastructure and Genexine's expertise in biologic drug development, KGbio aims to provide high quality and affordable innovative biologics and immuno-oncology products to Southeast Asian countries and beyond.
Rapidly Growing Pipeline with Two Products in Phase III Studies
In-licensed from Genexine
Efepoetin alfa or GX-E4 is a novel long-acting erythropoietin-hybrid Fc fusion protein. It is being evaluated in a phase III study for treatment of anemia related to chronic kidney disease in Southeast Asian countries, Taiwan and Australia.
In-licensed from Henlius
HLX10 is a humanized anti-PD1 monoclonal antibody. It is being evaluated for treatment of multiple tumor indications as well as chronic hepatitis B infection. KGBio has taken licenses for squamous non-small-cell lung cancer and hepatocellular carcinoma indications in which global phase III studies are in progress or about to start.
In-licensed from I-MAB Biopharma
Our passion for creating meaningful change for underserved patients is what sets us apart. The KGbio team believes in the potential of our great idea, and we work tirelessly in order to bring you a better tomorrow. We are proud of every single member of staff.
GET IN TOUCH
Kalbe building 3rd floor. Jl. Letjend Suprapto Kav 4, Jakarta 10510, Indonesia